RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Central Serous Chorioretinopathy: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Stellate Multiform Amelanotic Choroidopathy: Two Cases Mimicking a Choroidal Mass and Chronic Central Serous Chorioretinopathy.
Bezci Aygün Figen et al., Turkish journal of ophthalmology (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42876574/
- 2.
Oral eplerenone in first-episode acute central serous chorioretinopathy: results of a double-masked randomized trial.
Zamani Ghodsieh et al., International ophthalmology (12 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42864450/
- 3.
FLUORESCEIN ANGIOGRAPHY-GUIDED FOCAL LASER PHOTOCOAGULATION FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A REVIEW ARTICLE
MD1* Samah Said Ahmad Shirri, Zenodo (CERN European Organization for Nuclear Research) (10 October 2026)
https://doi.org/10.5281/zenodo.23277913
- 4.
Interpretable Machine Learning for Course Prediction in Central Serous Chorioretinopathy Using Baseline OCT from a Multicenter Cohort.
Lorenzo Ferro Desideri et al., Open Access CRIS of the University of Bern (8 October 2026)
https://doi.org/10.48620/101667
- 5.
Interpretable Machine Learning for Course Prediction in Central Serous Chorioretinopathy Using Baseline OCT from a Multicenter Cohort.
Desideri Lorenzo Ferro et al., American journal of ophthalmology (8 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42849862/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy
NCT05570591 · UNKNOWN · Nova Eye Medical Pty Ltd.
Ages 18 to 70
https://clinicaltrials.gov/study/NCT05570591
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Central Serous Chorioretinopathy
Central serous chorioretinopathy is an eye condition in which fluid builds up under the retina, the light-sensing layer at the back of the eye. It most often affects the central part of the retina, causing blurred or distorted vision, usually in one eye. It often settles on its own over a few months. Some people need laser or other treatments, and it can return.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Central Serous Chorioretinopathy?
Central serous chorioretinopathy is an eye condition in which fluid builds up under the retina, the light-sensing layer at the back of the eye. It most often affects the central part of the retina, causing blurred or distorted vision, usually in one eye. It often settles on its own over a few months. Some people need laser or other treatments, and it can return.
How many clinical trials are available for Central Serous Chorioretinopathy?
RareWays currently indexes 62 clinical trials for Central Serous Chorioretinopathy, of which 1 is actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Central Serous Chorioretinopathy come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Central Serous Chorioretinopathy.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.